For those that haven't already listened to the webcast? I...

For those that haven't already listened to the webcast? I suggest you do because there is some good stuff in there, things like this "Deal with major US Medtech" results of trial in Dec 2011?

and also this,
5.AOD9604 for fat reduction as an over the counter product.

Todays market action seems to indicate to me that someone may know something already?



http://webcast.viostream.com/Player/Default.aspx?viocast=4374&auth=67d99acf-408c-43fb-9f88-9bd911311884&enableCache=True


?Calzada owns 100% of Metabolic Pharma P/L and PolyNovo Biomaterials P/L
?There are five key projects underway
?These projects have been chosen with fast path to market and low to medium risk profile

?EPolyNovo has developed a suite of biodegradable polymers titled ??NovoSorb.??
?EField of biodegradable tissue scaffolds is growing rapidly with new cell therapies in development
?EKey advantages of NovoSorb. include:
??Flexible degradation time from weeks to years
??Possibility to tailor mechanical properties
??Near neutral pH of degradation products
??Easy to use and process using standard techniques
??Enables drug and biologic elution (antibacterial, antimicrobial, anesthetic)
??Fully synthetic
=> SAFE and EFFECTIVE

?Metabolic owns a peptide AOD9604 that has shown a good safety profile and some efficacy in human clinical trials in obesity
?However AOD9604 failed to meet the main clinical end point in the final Phase II clinical trial in 2007
?AOD9604 has been progressed in partnership with Phosphagenics Ltd to develop an effective anti cellulite cream as a cosmetic (BodyShaper?)
?AOD9604 has also demonstrated efficacy in animal models with prevention and treatment of osteoporosis and in vitro humanbone cell assays

1.NovoSorb? BioresorbableTemporizing Matrix (BTM)
?For treatment of full thickness burns
?Collaborator is burn surgeon A/Prof John Greenwood
?American Burns Association award
?Positive results in pig studies against market leader demonstrating no infection and less than half the contraction
?Currently in international safety trial (ISO10993) to prepare for clinical trial
?Pilot clinical trial planned early 2012
2.Smith and Nephew evaluating NovoSorb? in bone applications ?fracture fixation and void filler
3.Deal with major US Medtech-$400k option fee for 12 months for NovoSorb? evaluation in defined area
4.BodyShaper? cellulite cream AOD9604 royalties
?Positive results in clinical studies demonstrating cellulite reduction
?Launched in Australia through Myer with strong interest
?US launch expected later this year
5.AOD9604 for fat reduction as an over the counter product
?Investigating non-drug regulatory path to market ?Not yet confirmed
?Faster and cheaper than drug path
?Could include bone health claims as well